No drawback to the incorporation of dexamethasone in the standard therapy plan for CAP was found with respect to the pneumococcal immune response
No drawback to the incorporation of dexamethasone in the standard therapy plan for CAP was found with respect to the pneumococcal immune response. Footnotes Published ahead of printing 29 February…